The Chia Tai Tianqing Patent Portfolio offers a useful lens into how one of China’s leading pharmaceutical groups builds and defends its innovation base. Across 1,486 total patent families, 78.7% remain active when combining granted and pending cases. Of these, 716 families have been granted and 453 are still pending before patent offices, giving a grant rate of 48.2%. A combined 317 families have lapsed, expired or been revoked. These figures reflect prosecution and maintenance status only, not a judgment on patent quality or enforceability.
Filing activity peaked in 2024, when the company filed 135 new patent families, the highest single-year count in the dataset. China dominates the filing geography, accounting for 92.7% of the portfolio across a total of 10 jurisdictions tracked. The leading technology cluster is A61K (preparations for medical purposes), with 985 families, making it the single largest classification in the portfolio by a clear margin.
This article is intended to help readers interpret the shape and direction of Chia Tai Tianqing’s patent filings, not to draw conclusions about commercial outcomes. Filing counts alone do not establish product success, market share or competitive advantage in any therapeutic area. Readers considering business or research decisions based on specific patent families should independently verify those filings before external use. The analysis that follows focuses on composition, trend, geography and technology concentration as observable signals, each useful for forming a broader view of the company’s research priorities and protection strategy.
About Chia Tai Tianqing
Company Profile: Chia Tai Tianqing Pharmaceutical Group, known as CTTQ, is a Chinese pharmaceutical company. CTTQ is a multinational pharmaceutical company with integrated R&D, manufacturing, marketing, sales and distribution capabilities. It is the core enterprise of Sino Biopharmaceutical, listed on the Hong Kong exchange as 01177.HK. With more than 14,000 employees, CTTQ is well-known in the field of anti-tumor and liver disease in China, and ranked 15th on the list of Top 100 Pharmaceutical Enterprises in China in 2020. The company originated from a pharmaceutical factory founded in 1969 in Jiangsu province.
It supplies liver disease, cancer, cardiovascular, anti-infective, digestion, respiratory, and diabetes medicinal products. CTTQ sells its products domestically and internationally. Headquartered in Lianyungang, Jiangsu, the company has pursued strategic pharmaceutical partnerships and licensing deals, including agreements with global firms for novel drug candidates, reflecting its growing international R&D and commercialization ambitions.
How Healthy is Chia Tai Tianqing Patent Portfolio?
Patent portfolio health depends on the balance between granted protection, pending applications and attrition. Chia Tai Tianqing shows 48.2% of its families granted and 30.5% still pending, per the legal status figures. That gives an active rate of 78.7%, a reasonably strong position for a company with this filing volume. On the attrition side, 13.1% of families have lapsed, 5.1% have been revoked and 3.1% have expired, together forming a modest but visible share.
The composition chart in this section also shows patent type is heavily skewed toward utility patents, at 96.1% of filings, with utility models at 3.6% and design filings at just 0.3%. This pattern is typical for a pharmaceutical innovator, where chemical compounds, formulations and methods of treatment require full patent protection rather than utility model or design routes. The low revocation and expiry share suggests the portfolio is being actively maintained rather than allowed to erode. Pending share above 30% also indicates a meaningful pipeline of applications still working through examination, which could convert into granted rights over the coming years.
How Has the Chia Tai Tianqing Patent Portfolio Evolved Over Time?
Patent filing trends for Chia Tai Tianqing show a long building phase followed by stronger, more consistent activity from the mid-2010s onward. Early years saw modest counts, with 24 families in 2008 and similarly low levels through 2012. Filings rose sharply from 2013 (64) through 2016 (106), then held in a broadly similar range before climbing again to a peak of 135 families in 2024, as shown in the filing-trend chart.
The most recent two years, 2025 and 2026, show lower counts of 82 and 24 respectively, reflecting a -70.7% change versus the prior year. This drop should be read cautiously. Publication lag means recently filed applications often take twelve to eighteen months to appear in public databases, so these figures likely understate real filing activity rather than signal a genuine slowdown. The broader decade-long pattern, featuring year after year above 80 filings since 2015, points to a sustained and deliberate R&D investment rather than a one-off surge. This sustained volume supports continued confidence in the company’s innovation pipeline.
Where Does the Chia Tai Tianqing Patent Portfolio Prioritize Patent Protection?
Patent geography for Chia Tai Tianqing is heavily anchored in its home market. China accounts for 1,378 families, or 92.7% of the portfolio, by far the largest share among the 10 jurisdictions tracked. This is expected for a company whose primary commercial base and manufacturing footprint sit in China, but it also signals where enforcement and competitive risk concentrate most heavily.
Beyond China, filings under the WIPO PCT route lead international protection, covering 33.8% of the portfolio with 503 families, a common strategy for deferring country-specific decisions. Europe and the United States follow, at 17.0% and 16.7% respectively, with Japan at 12.7%. Hong Kong, Australia and Canada each sit close together around 11.6% to 11.7%, while South Korea and Taiwan trail at 9.2% and 9.0%. The geographic chart in this section shows a clear tiering: China as the core, PCT as the bridge to international markets, and a second tier of developed-market jurisdictions receiving selective, deliberate protection rather than blanket filing.
Where is the Chia Tai Tianqing Patent Portfolio Building Protection Across Key Technologies?
IPC analysis of the Chia Tai Tianqing Patent Portfolio points clearly toward pharmaceutical compound and formulation science. The technology chart in this section shows A61K (preparations for medical purposes) leading with 985 families, or 30.2% of classified filings. Close behind is A61P, covering specific therapeutic activity of compounds, at 972 families and 29.8%, confirming a strong focus on treatment-specific applications rather than generic formulation work alone.
C07D (heterocyclic compounds), a core medicinal chemistry classification, holds 673 families at 20.6%, reinforcing small-molecule drug development as a central competency. Smaller but notable clusters include C07K (peptides) at 5.3% and C07C (acyclic compounds) at 3.4%. Categories like G01N (investigating or analysing materials) at 2.8% and C12N (micro-organisms, enzymes) at 2.3% suggest complementary investment in diagnostics and biotechnology tools alongside core drug development. Together, these clusters show a portfolio built around therapeutic compound innovation, with supporting capability in analytical and biological methods.
How Has the Chia Tai Tianqing Patent Portfolio Evolved Across Filing Geographies?
The heatmap view of filings by year and jurisdiction reveals how China and international markets have moved somewhat differently over the past decade. China filings rose from 65 in 2014 to a high of 124 in 2021, before settling to 111 in 2023, consistently the largest share in every year observed. WIPO PCT filings grew steadily too, from 22 in 2014 to 59 in 2021, tracking China’s pattern with a short lag typical of PCT’s later national-phase entry timeline.
The United States and Europe tell a different story. US filings rose to 40 in 2020 and 39 in 2021, then fell sharply to 11 in 2022 and just 2 in 2023. EP filings show a similar late decline, from 38 in 2020 to 17 in 2023. This likely reflects publication lag for the most recent application years rather than a deliberate pullback from these markets. Jurisdictions like Taiwan and Canada show more volatility year to year, consistent with smaller absolute filing volumes and more selective, case-by-case filing decisions in those markets.
Consultant’s Perspective on Chia Tai Tianqing Patent Portfolio
From an advisory standpoint, the Chia Tai Tianqing Patent Portfolio reflects a maturing innovator transitioning from a domestically focused filer to one with deliberate, if selective, international reach. The 92.7% China concentration is appropriate given the company’s manufacturing and commercial base, but the comparatively thinner coverage in the United States and Europe, especially in the most recent filing years, deserves closer monitoring. Whether this reflects publication lag or an actual strategic recalibration will become clearer as 2024 to 2026 filings fully populate public databases.
The technology concentration in A61K, A61P and C07D confirms a portfolio built around core small-molecule and therapeutic compound innovation, consistent with the company’s known strength in oncology and liver disease treatment. The 78.7% active rate and healthy pending share suggest the company continues to invest in prosecution rather than letting filings lapse. For competitors, licensing partners or investors assessing this portfolio, the recommended next step is a family-level review of recent China and PCT filings. These are likely to reveal the clearest signal of where Chia Tai Tianqing intends to compete over the next five years.
Explore Deeper Insights with Expertlancing Research
This overview of the Chia Tai Tianqing Patent Portfolio only scratches the surface of what a detailed, family-level review can reveal. Expertlancing Research helps clients go further, mapping competitor filings, tracking technology white space, and assessing specific patent families for licensing, due diligence or freedom-to-operate purposes. If you are evaluating Chia Tai Tianqing or its peers for a business decision, our analysts can build a tailored intelligence brief around your specific question. Reach out to Expertlancing Research to discuss how we can support your next strategic review.